126 related articles for article (PubMed ID: 22043058)
1. Gene profiling assay and application: the predictive role in primary therapy.
Fumagalli D; Desmedt C; Ignatiadis M; Loi S; Piccart M; Sotiriou C
J Natl Cancer Inst Monogr; 2011; 2011(43):124-7. PubMed ID: 22043058
[TBL] [Abstract][Full Text] [Related]
2. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
4. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
5. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
Nagasaki K; Miki Y
Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
[TBL] [Abstract][Full Text] [Related]
6. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.
Generali D; Symmans WF; Berruti A; Fox SB
J Natl Cancer Inst Monogr; 2011; 2011(43):99-102. PubMed ID: 22043052
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.
Chow LW
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025
[TBL] [Abstract][Full Text] [Related]
8. Prognostic markers of local relapse in rectal cancer: are we any further forward?
Johnston PG
J Clin Oncol; 2006 Sep; 24(25):4049-50. PubMed ID: 16943520
[No Abstract] [Full Text] [Related]
9. Biomarkers predicting clinical benefit: fact or fiction?
Guarneri V; Barbieri E; Conte P
J Natl Cancer Inst Monogr; 2011; 2011(43):63-6. PubMed ID: 22043043
[TBL] [Abstract][Full Text] [Related]
10. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
Colleoni M; Viale G; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S137-40. PubMed ID: 19914533
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in breast cancer.
Morris SR; Carey LA
Curr Opin Oncol; 2007 Nov; 19(6):547-51. PubMed ID: 17906450
[TBL] [Abstract][Full Text] [Related]
12. [New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F; Sergi D; Foggi P; Abbate MI; Lopez M
Clin Ter; 2007; 158(1):55-75. PubMed ID: 17405660
[TBL] [Abstract][Full Text] [Related]
13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Wurster M; Ruoff A; Meisner C; Seeger H; Vogel U; Juhasz-Böss I; Solomayer E; Wallwiener D; Fehm T; Neubauer H
Oncol Rep; 2010 Sep; 24(3):653-9. PubMed ID: 20664970
[TBL] [Abstract][Full Text] [Related]
15. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
Correa Geyer F; Reis-Filho JS
Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
[TBL] [Abstract][Full Text] [Related]
19. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles.
Mehta S; Hughes NP; Buffa FM; Li SP; Adams RF; Adwani A; Taylor NJ; Levitt NC; Padhani AR; Makris A; Harris AL
J Natl Cancer Inst Monogr; 2011; 2011(43):71-4. PubMed ID: 22043045
[TBL] [Abstract][Full Text] [Related]
20. Surrogate markers for targeted therapy-based treatment activity and efficacy.
Bianchini G; Gianni L
J Natl Cancer Inst Monogr; 2011; 2011(43):91-4. PubMed ID: 22043050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
